HOMEPAGE
Fully Diluted Subscribe

NYSE · Biotech stocks database

CATX — Perspective Therapeutics Inc.

CATX (Perspective Therapeutics Inc.) stock: $0.81, $93.0M market cap, $201.7M cash, -$107.1M EV, $109.1M fully diluted market cap. Lead program: [203Pb]VMT01 (Recurrent Melanoma (Skin)), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 ( 212 Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Source: 10-K FY2025 via SEC EDGAR

Share price
$0.81
Market cap
$93.0M
Cash
$201.7M
Enterprise value
-$107.1M

Balance sheet

Cash$201.7M
Debt$1.6M
Net cash$200.1M
Enterprise value-$107.1M
Basic shares120.8M shares
Fully diluted shares134.7M shares
Fully diluted market cap$109.1M
Cash per share$1.67
Quarterly burn$20.6M
Cash runway11.5 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common
114.2M
Pre-funded warrants
6.6M
Options
13.6M
RSUs
0.0M
Warrants
0.3M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
134.7M

Cap table as of 2026-06-30.

Price history

Loading CATX daily closes…

Loading price history…

Next catalyst

[203Pb]Pb-PSV359 · Mar 13 - Apr 24 in 16 mo · Phase 1/2 · Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer

Recently reported

[203Pb]VMT01 Phase 1/2a Mixed · 2026-11-06
Primary: Interim antitumor activity and safety of lapemelanotide monotherapy across three dose cohorts in the Phase 1/2a study (the release does not name a formal primary endpoint for this interim update) — At the program's focus dose of 3.0 mCi, two out of the eight patients enrolled in the monotherapy cohort had objective partial responses; the disease control rate (DCR) was 75%
· 20 patients received at least one monotherapy treatment as of the September 18, 2026 data cutoff, across three dose cohorts of up to cumulative 4.5 mCi, 9 mCi, and 15 mCi
· One of the two confirmed responders remains in partial response and on study approximately 40 weeks after their first treatment
· Grade 3 or higher TEAEs occurred in five patients (25%), with none considered treatment-related
Safety: No dose-limiting toxicities (DLTs), treatment-related serious treatment-emergent adverse events (TEAEs), or adverse event-related treatment discontinuations were reported across all 20 monotherapy patients
Source release →
[212Pb] Phase 1/2a Positive · 2026-11-05
neuroendocrine tumors, neuroendocrine tumor of the lung, neuroendocrine tumor grade 1
Primary: Landmark progression-free survival, disease control rate and objective response rate in GEP-NET patients whose target lesions all express SSTR2 (Phase 1/2a dose-finding trial of bamzireotide) — PFS was 75% at 18 months across Cohorts 1-3 in the 57-patient SSTR2-positive subgroup; disease control was 92% in Cohort 2 and 100% in Cohort 3
· Responses in 14 of 38 Cohort 2 patients (37%) and 8 of 17 Cohort 3 patients (47%) in the SSTR2-positive subgroup
· PFS rate was 91% at six months and 78% at 12 months across Cohorts 1, 2 and 3 in the subgroup
· Across all 68 treated patients, Grade 3 treatment-emergent adverse events occurred in 20 patients (29%), with no Grade 4 or 5 events
· Grade 3 hematologic treatment-emergent adverse events occurred in five of 68 patients (7.4%)
· Two patients (3%) experienced Grade 3 renal events during follow-up
· Company is targeting an End-of-Phase 2 meeting in the first quarter of 2027
Safety: No dose-limiting toxicities, no treatment-related discontinuations, and no serious adverse events related to study medication; bamzireotide continues to be well-tolerated
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego